Fig. 3From: Cost-utility analysis of Palbociclib + letrozole and ribociclib + letrozole versus Letrozole monotherapy in the first-line treatment of metastatic breast cancer in Iran using partitioned survival modelPFS curves of compared strategies according to the economic evaluation time horizon in the first-line treatment of HR + / HER2- MBCBack to article page